Author:
Langsjoen-P-H. Langsjoen-P-H.
Folkers-K.
Source:
Int-J-Tissue-React. 1990. 12(3). P 169-71.
Journal
Title: INTERNATIONAL JOURNAL OF TISSUE
REACTIONS.
Abstract:
One hundred and forty-three cases of
chronic, stable, non- secondary, non-hypertrophic
cardiomyopathy, 98% of whom were in NYHA Classes III and IV,
were given 100 mg of coenzyme Q10** orally in addition to
their conventional medical programme in an open-label
long-term study. Blood CoQ10 levels, clinical status,
myocardial function and survival have been recorded now for
almost 6 years. Mean control/CoQ10 levels of 0.85
micrograms/ml rose to 2 micrograms/ml in 3 months and remained
stable at that level. Mean ejection fraction of 44% measured
by systolic time interval analysis rose to 60% within 6 months
and stabilized at that level with 84% of patients showing
statistically significant improvement. Eighty-five percent of
patients improved by one or two NYHA Classes. Survival figures
were encouraging with an 11.1% mortality in 12 months and
17.8% mortality in 24 months, comparing favourably with
several reports in the literature. There was no positive
evidence of toxicity or intolerance in a total of 368.9
patient-years of exposure. Coenzyme Q10 is safe and effective
long-term therapy for chronic cardiomyopathy.
